[Correlation between the prognosis of medulloblastoma and relevant clinical factors: analysis of 73 cases].
OBJECTIVE
To analyze the correlation between the prognosis of medulloblastoma (MB) and relevant clinical factors.


METHODS
Seventy-three MB patients, 48 males and 25 females, aged 13.6 (2 approximately 40), underwent surgical treatment and part of them underwent radiotherapy and/or chemotherapy. Follow-up was conducted among 55 cases for 40.0 months (2 months approximately 8 years and 5 months). The correlation between the prognosis and the clinical factors, such and sex, age, tumor location, extent of tumor resection, brainstem invasion, radiotherapy, chemotherapy, ventriculoperitoneal shunt and glial differentiation was analyzed.


RESULTS
Six patients died postoperatively, and average survival time of the other 49 patients was 61 months. Twenty patients had a survival time of 3 years after operation, and the 3-year survival rate was 63.98%; and 8 patients survived for 5 years after operation with a 5-year survival rate of 43%. The prognosis Analysis showed that only radiotherapy was the only influencing factor of survival time. Those undergoing whole brain/posterior fossa plus spinal axis radiotherapy showed a better prognosis than those undergoing whole brain/posterior fossa radiotherapy.


CONCLUSIONS
The prognosis of MB is not good; yet, surgical resection with regular radiotherapy and chemotherapy is helpful for the prognosis of MB.
Yang
Liu-song
LS
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Wang
Yu-qian
YQ
Huang
Feng-ping
FP
D000293:Adolescent; D000328:Adult; D016543:Central Nervous System Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008527:Medulloblastoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate